Home / Market News / $RYTM

$RYTM news and market catalysts

The 21 most recent market catalysts affecting $RYTM, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

21 catalysts 6 high impact 15 bullish 0 bearish Biotechnology
Nov 16, 2026 Corporate Catalyst Bullish Impact 75
Rhythm Pharmaceuticals Announces New Clinical Data for Setmelanotide in Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals disclosed new, positive clinical data for setmelanotide in acquired hypothalamic obesity from its TRANSCEND trial. The reported -18.8% mean BMI change at two…
Nov 6, 2026 Corporate Catalyst Bullish Impact 95
Rhythm Pharmaceuticals Gains on Report of Additional Bidder
Rhythm Pharmaceuticals' stock surged on reports of a second potential bidder, indicating a competitive acquisition scenario. This development is significant because it could drive …
Nov 5, 2026 Corporate Catalyst Neutral Impact 95
AstraZeneca Makes $10 Billion Takeover Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly submitted a $10 billion takeover offer for Rhythm Pharmaceuticals, valuing the company at $124 per share. This move aligns with AstraZeneca's strategic g…
Nov 5, 2026 Corporate Catalyst Neutral Impact 95
AstraZeneca Makes $10 Billion Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly offered $10 billion, or $124 per share, to acquire Rhythm Pharmaceuticals. This potential acquisition is significant as it directly supports AstraZeneca'…
Nov 4, 2026 Corporate Catalyst Bullish Impact 85
Rhythm Pharmaceuticals Announces Positive Phase 2 Results for Bivamelagon
Rhythm Pharmaceuticals reported positive Phase 2 results for bivamelagon in treating acquired hypothalamic obesity. This is a significant milestone for the company as it de-risks t…
Nov 3, 2026 Corporate Catalyst Neutral Impact 55
Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results
Rhythm Pharmaceuticals filed an 8-K to announce its third-quarter 2026 financial results and provide a business update. The key takeaway is the continued commercial momentum of IMC…
Nov 3, 2026 Corporate Catalyst Bullish Impact 85
Rhythm Pharmaceuticals Amends Bivamelagon Licensing Agreement and Secures $750 Million Financing
Rhythm Pharmaceuticals (RYTM) has significantly altered its financial and operational landscape. The amendment to the bivamelagon licensing agreement with LG Chem involves both inc…
Nov 3, 2026 Corporate Catalyst Bullish Impact 75
KKR Provides Financing to Rhythm Pharmaceuticals
Rhythm Pharmaceuticals has secured up to $750 million in financing from KKR and Blackstone, a substantial capital injection aimed at advancing its experimental obesity drug, bivame…
Oct 16, 2026 Corporate Catalyst Neutral Impact 65
William Blair Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating
William Blair, a reputable investment bank, has initiated coverage on Rhythm Pharmaceuticals with an 'Outperform' rating. This event is significant because new analyst coverage, es…
Oct 14, 2026 Corporate Catalyst Bullish Impact 75
Reported Earlier, Rhythm Pharmaceuticals Launches IMCIVREE In Japan As First Approved Therapy For Acquired Hypothalamic Obesity, Backed By Phase 3 TRANSCEND Trial Showing 18.8% Placebo-Adjusted BMI Reduction
This headline is a significant positive catalyst for Rhythm Pharmaceuticals (RYTM). The launch of IMCIVREE in Japan, a major pharmaceutical market, for a rare but serious condition…
Oct 12, 2026 Corporate Catalyst Bullish Impact 65
HC Wainwright & Co. Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $130
HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a 'Buy' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target from $105 to $130. This action signals inc…
Oct 8, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $159
RBC Capital analyst Lisa Walter maintained an 'Outperform' rating for Rhythm Pharmaceuticals and raised the price target from $155 to $159. This action signals continued bullish se…
Aug 28, 2026 Corporate Catalyst Neutral Impact 55
Deutsche Bank Initiates Coverage On Rhythm Pharmaceuticals with Hold Rating, Announces Price Target of $120
Deutsche Bank analyst David Hoang has initiated coverage on Rhythm Pharmaceuticals (RYTM) with a 'Hold' rating and a $120 price target. This event is significant for RYTM as it int…
Aug 12, 2026 Corporate Catalyst Bullish Impact 75
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday?
Rhythm Pharmaceuticals received expanded marketing authorization from the UK's MHRA for its drug Imcivree (setmelanotide) to treat acquired hypothalamic obesity (HO) in adults and …
Aug 7, 2026 Corporate Catalyst Bullish Impact 55
JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146
JP Morgan analyst Priyanka Grover maintained an 'Overweight' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target by a modest $1, from $145 to $146. This action sign…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $143
Citigroup analyst Samantha Semenkow maintained a 'Buy' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target from $142 to $143. This action signals continued positive…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
RBC Capital's analyst Lisa Walter has reiterated an 'Outperform' rating for Rhythm Pharmaceuticals and raised the price target from $141 to $155. This action signals continued conf…
Aug 5, 2026 Corporate Catalyst Bullish Impact 55
Citizens Maintains Market Outperform on Rhythm Pharmaceuticals, Raises Price Target to $160
Citizens analyst Jonathan Wolleben maintained a 'Market Outperform' rating on Rhythm Pharmaceuticals (RYTM) and raised the price target from $155 to $160. This action signals conti…
Aug 4, 2026 Corporate Catalyst Bullish Impact 75
Rhythm Pharmaceuticals Announces Preliminary Results From Ongoing Phase 2 Trial Evaluating RM-718 In Patients With Acquired Hypothalamic Obesity; BMI Reductions Consistent With Setmelanotide And Bivamelagon; Sees -11.6% Mean Reduction In BMI From Baseline At Week
Rhythm Pharmaceuticals released encouraging preliminary Phase 2 data for RM-718, its drug candidate for acquired hypothalamic obesity (HO). The -11.6% mean BMI reduction is signifi…
Jul 27, 2026 Corporate Catalyst Bullish Impact 85
Rhythm Pharmaceuticals shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $145 price target.
This headline represents a significant corporate catalyst for Rhythm Pharmaceuticals. An 'Overweight' rating from a major investment bank like JP Morgan, coupled with a high price …
Jul 27, 2026 Corporate Catalyst Neutral Impact 65
JP Morgan Initiates Coverage On Rhythm Pharmaceuticals with Overweight Rating, Announces Price Target of $145
JP Morgan's initiation of coverage on Rhythm Pharmaceuticals with an 'Overweight' rating and a $145 price target is a significant event for the company. Analyst initiations, especi…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.